Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health
11:05am, Tuesday, 28'th Apr 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, ann
Clearside Biomedical appoints Nancy Hutson to board of directors CLSD;PFE
11:46am, Wednesday, 22'nd Apr 2020
Clearside Biomedical appoints Nancy Hutson to board of directors CLSD PFE
Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors
11:05am, Wednesday, 22'nd Apr 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, ann
Needham Sticks to Its Hold Rating for Clearside Biomedical (CLSD)
09:38am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD) today. The company's shares closed last Wednesday at $2.41.
Needham Sticks to Its Hold Rating for Clearside Biomedical (CLSD)
09:38am, Thursday, 16'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD – Research Report) today. The company’s shares closed
Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians
11:05am, Thursday, 09'th Apr 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, ann
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
11:05am, Wednesday, 08'th Apr 2020
ALPHARETTA, Ga., April 08, 2020 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and.
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
04:10pm, Sunday, 29'th Mar 2020
After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coronavirus (COVID-19) news flow continued to dominate
CCL, EXPE among premarket losers
01:25pm, Thursday, 12'th Mar 2020
ZAGG (NASDAQ:ZAGG) -44% after ending strategic review with no deal and Q4 earnings.Sasol (NYSE:SSL) -37%.Party City Holdco (NYSE:PRTY) -36% on Q4 earnings.Norwegian Cruise Line Holdings (NYSE:NCLH
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
09:43am, Thursday, 12'th Mar 2020
In a report released today, Serge Belanger from Needham maintained a Hold rating on Clearside Biomedical (CLSD). The company's shares closed last Monday
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
09:43am, Thursday, 12'th Mar 2020
In a report released today, Serge Belanger from Needham maintained a Hold rating on Clearside Biomedical (CLSD – Research Report).
Edited Transcript of CLSD earnings conference call or presentation 11-Mar-20 8:30pm GMT
07:00am, Thursday, 12'th Mar 2020
Q4 2019 Clearside Biomedical Inc Earnings Call
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
5 Stocks Moving In Wednesday's After-Hours Session
08:48pm, Wednesday, 11'th Mar 2020
Gainers
Clearside Biomedical (NASDAQ: CLSD) shares are trading higher after the company announced a license agreement with Arctic Vision. The company also reported better-...
Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
08:05pm, Wednesday, 11'th Mar 2020
- IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 -- Greater China Licensing Partnership and Updated NDA Resubmission Timeline for XIPERE™.
